<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00744055</url>
  </required_header>
  <id_info>
    <org_study_id>00032</org_study_id>
    <nct_id>NCT00744055</nct_id>
  </id_info>
  <brief_title>Prazosin for Treatment of Patients With Alcohol Dependence (AD) and Post Traumatic Stress Disorder (PTSD).</brief_title>
  <official_title>The Use of Prazosin for Treatment of Patients With Alcohol Dependence (AD) and Post Traumatic Stress Disorder (PTSD).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prazosin is an alpha-1 adrenergic receptor antagonist that has been used successfully in the
      treatment of trauma nightmares and sleep disturbance in combat veterans with PTSD, and
      alcohol dependence.

      The objective of this study is to evaluate the efficacy of prazosin (16mg) versus placebo in
      reducing alcohol consumption and decreasing symptoms of PTSD in patients with comorbid AD and
      PTSD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

      There is a high rate of comorbidity with alcohol dependence (AD) and post traumatic stress
      disorder (PTSD). The rates of PTSD among individuals with AD are at least twice as high as
      those in the general population. In addition, alcohol dependence is the most common comorbid
      condition in men with PTSD. Despite this, little is known about how to best treat individuals
      with comorbid AD and PTSD. The use of an alpha-1 adrenergic receptor antagonist represents a
      novel approach to treatment that may target symptoms of both AD and PTSD. There is evidence
      of common neurobiological mechanisms that underlie both AD and PTSD. Prazosin is an alpha-1
      adrenergic receptor antagonist that has been used successfully in the treatment of trauma
      nightmares and sleep disturbance in combat veterans with PTSD, and alcohol dependence.

      Objective:

      The objective of this study is to evaluate the efficacy of prazosin (16mg) versus placebo in
      reducing alcohol consumption and decreasing symptoms of PTSD in patients with comorbid AD and
      PTSD. Methods: Thirty participants with a current diagnosis of AD and PTSD will be enrolled
      in a 13-week trial. They will be assigned, in a double-blind fashion, to either prazosin or
      placebo. Significance: This project will be the first to compare prazosin to placebo as
      effective treatments for reducing alcohol consumption and PTSD symptoms in patients with both
      AD and PTSD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Drinking Days</measure>
    <time_frame>12 weeks</time_frame>
    <description>Using the Timeline Follow Back method, a calendar method for assessing drug and alcohol use</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinician-Administered PTSD Scale</measure>
    <time_frame>12 weeks</time_frame>
    <description>Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). A higher score is associated with higher severity of PTSD. The score is interpreted as follows: 0-19=Asymptomatic/few symptoms 20-39=Sub-threshold/mild PTSD 40-59=Threshold PTSD/moderate 60-79=Severe PTSD &gt;80=Extreme PTSD</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Alcohol Dependence</condition>
  <condition>Stress Disorders, Post-Traumatic</condition>
  <arm_group>
    <arm_group_label>Prazosin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>prazosin (16mg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo in identical looking capsule blister packs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prazosin</intervention_name>
    <description>prazosin (16mg/day) 2 times a day</description>
    <arm_group_label>Prazosin</arm_group_label>
    <other_name>Minipress</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females between the ages of 21-65 years old.

          2. Current alcohol dependence, as determined by a structured clinical interview
             (Structured Clinical Interview for DSM-IV Axis I Disorders) (SCID) (First et al.
             1996).

          3. Current PTSD as determined by the Clinician Administered PTSD Scale for DSM-IV(CAPS)
             (Blake et al. 1995).

          4. Patients with current alcohol dependence, with at least one recent episode of heavy
             drinking (defined as 5 or more drinks per drinking episode) over the past 14 days.

          5. Medically and neurologically healthy on the basis of history, physical examination,
             EKG, screening laboratories (CBC w/ differential, TSH, Free-T4, ASAT, ALAT, GGT, BUN,
             creatinine, calcium, phosphorous, magnesium, total protein, albumin, electrolytes,
             VDRL, urinalysis, beta-HCG).

          6. For women, negative pregnancy test and use of acceptable method of contraception.

        Exclusion Criteria:

          1. Females who are pregnant or lactating.

          2. Individuals with a current unstable medical condition such as neurological,
             cardiovascular, endocrine, renal, liver, or thyroid pathology (LFT 5 times normal,
             abnormal BUN and creatinine, and unmanaged hypertension with BP more than 200/120)
             which in the opinion of the physician would preclude the patient from fully
             cooperating or be of potential harm during the course of the study.

          3. Patients who meet current SCID criteria for the following major Axis I diagnoses
             (Bipolar Disorders, Schizophrenia and Schizophrenia-type Disorders).

          4. History of substance dependence (other than alcohol, cocaine, tobacco or cannabis) by
             DSM-IV criteria in the last 30 days.

          5. Individuals taking mood stabilizers and antipsychotic medications.

          6. Individuals with a history of sensitivity to quinazolines or prazosin.

          7. Individuals taking medications thought to influence alcohol consumption (naltrexone,
             disulfiram, acamprosate).

          8. Individuals taking adrenergic medication (e.g. clonidine).

          9. Agents that may interact with prazosin such as drugs with CNS depressant effects
             including tizanidine and xyrem.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ismene Petrakis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Connecticut Healthcare System</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 28, 2008</study_first_submitted>
  <study_first_submitted_qc>August 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2008</study_first_posted>
  <results_first_submitted>October 27, 2015</results_first_submitted>
  <results_first_submitted_qc>December 11, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 18, 2016</results_first_posted>
  <last_update_submitted>March 18, 2016</last_update_submitted>
  <last_update_submitted_qc>March 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>alcohol dependence</keyword>
  <keyword>post traumatic stress disorder</keyword>
  <keyword>treatment</keyword>
  <keyword>prazosin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Prazosin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Randomization was conducted by the pharmacy using a 1:1 randomization in blocks of 4 and stratified by site, gender.
Completers were defined as subjects for whom we had complete data at the end of the treatment period (week 12) whether they remained on medication or not.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Prazosin</title>
          <description>prazosin (16mg/day)
Prazosin: prazosin (16mg/day) 2 times a day</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo in identical looking capsule blister packs
Placebo: Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Veterans</population>
      <group_list>
        <group group_id="B1">
          <title>Prazosin</title>
          <description>men or women, ages of 21-65, met DSM-IV criteria for current PTSD and alcohol dependence (AD) (determined by structured clinical interview)</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>men or women, ages of 21-65, met DSM-IV criteria for current PTSD and alcohol dependence (AD) (determined by structured clinical interview)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="46"/>
            <count group_id="B3" value="96"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.5" spread="13.2"/>
                    <measurement group_id="B2" value="43.40" spread="12.95"/>
                    <measurement group_id="B3" value="43.96" spread="12.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PTSD Symptoms</title>
          <description>Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV). The scale consists of 30 questions on a scale from 0-4.
The lowest possible score is 0 and the highest possible score is 120. A higher score is associated with higher severity of PTSD. The score is interpreted as follows: 0-19=Asymptomatic/few symptoms 20-39=Sub-threshold/mild PTSD 40-59=Threshold PTSD/moderate 60-79=Severe PTSD &gt;80=Extreme PTSD</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.86" spread="20.32"/>
                    <measurement group_id="B2" value="75.86" spread="14.44"/>
                    <measurement group_id="B3" value="73.7" spread="17.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Average Drinks Per Drinking Day</title>
          <units>drinks per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.33" spread="10.73"/>
                    <measurement group_id="B2" value="21.90" spread="13.24"/>
                    <measurement group_id="B3" value="19.53" spread="8.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Drinking Days</title>
        <description>Using the Timeline Follow Back method, a calendar method for assessing drug and alcohol use</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prazosin</title>
            <description>prazosin (16mg/day)
Prazosin: prazosin (16mg/day) 2 times a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo in identical looking capsule blister packs
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Drinking Days</title>
          <description>Using the Timeline Follow Back method, a calendar method for assessing drug and alcohol use</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.04" spread="18.86"/>
                    <measurement group_id="O2" value="9.21" spread="16.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinician-Administered PTSD Scale</title>
        <description>Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). A higher score is associated with higher severity of PTSD. The score is interpreted as follows: 0-19=Asymptomatic/few symptoms 20-39=Sub-threshold/mild PTSD 40-59=Threshold PTSD/moderate 60-79=Severe PTSD &gt;80=Extreme PTSD</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prazosin</title>
            <description>prazosin (16mg/day)
Prazosin: prazosin (16mg/day) 2 times a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo in identical looking capsule blister packs
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Clinician-Administered PTSD Scale</title>
          <description>Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). A higher score is associated with higher severity of PTSD. The score is interpreted as follows: 0-19=Asymptomatic/few symptoms 20-39=Sub-threshold/mild PTSD 40-59=Threshold PTSD/moderate 60-79=Severe PTSD &gt;80=Extreme PTSD</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.94" spread="37.62"/>
                    <measurement group_id="O2" value="37.93" spread="41.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Prazosin</title>
          <description>prazosin (16mg/day)
Prazosin: prazosin (16mg/day) 2 times a day</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo in identical looking capsule blister packs
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fainting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Falling</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol Relapse</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Homocidal Ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Partial thrombus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Elizabeth Ralevski</name_or_title>
      <organization>Yale University School Of Medicine Department of Psychiatry</organization>
      <phone>2039325711 ext 4282</phone>
      <email>elizabeth.ralevski@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

